NVWM LLC’s Cytokinetics CYTK Stock Holding History

NVWM LLC’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$777K	Sell	9,123 -94	-1%	-$6.75K	0.16%	145
2026 Q1	$607K	Buy	+9,217	New	+$586K	0.14%	163

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NVWM LLC's CYTK Position: Q2 2026 in Review

NVWM LLC reduced its Cytokinetics (CYTK) stake by 1% in Q2 2026, selling an estimated $6.75K and leaving 9,123 shares worth $777K. The position accounts for 0.16% of the portfolio, ranked #145.

NVWM LLC first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

NVWM LLC held 9,123 shares of Cytokinetics worth $777K as of Q2 2026.
NVWM LLC sold 94 Cytokinetics shares in Q2 2026, an estimated $6.75K.
Cytokinetics made up 0.16% of NVWM LLC's portfolio in Q2 2026, its #145 holding.
NVWM LLC first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on NVWM LLC's 13F filing for Q2 2026, filed 29 Jul 2026.